These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 20636829)

  • 1. Anti-platelets in diabetes management.
    Grantham NM; Magliano DJ; Tai G; Cohen N; Shaw JE
    Intern Med J; 2010 Jun; 40(6):458-62. PubMed ID: 20636829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk factor management is poorer in diabetic patients with undiagnosed peripheral arterial disease than in those with known coronary heart disease or cerebrovascular disease. Results of a nationwide study in tertiary diabetes centres.
    González-Clemente JM; Piniés JA; Calle-Pascual A; Saavedra A; Sánchez C; Bellido D; Martín-Folgueras T; Moraga I; Recasens A; Girbés J; Sánchez-Zamorano MA; Mauricio D;
    Diabet Med; 2008 Apr; 25(4):427-34. PubMed ID: 18341592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
    Lim HS; Blann AD; Lip GY
    Circulation; 2004 Jun; 109(21):2524-8. PubMed ID: 15136493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes.
    Owen AJ; Retegan C; Rockell M; Jennings G; Reid CM
    Clin Exp Pharmacol Physiol; 2009 Jul; 36(7):643-7. PubMed ID: 19076166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
    Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.
    Bulatova NR; Yousef AM; AbuRuz SM
    Thromb Res; 2007; 121(1):43-50. PubMed ID: 17462716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
    Singla A; Antonino MJ; Bliden KP; Tantry US; Gurbel PA
    Am Heart J; 2009 Nov; 158(5):784.e1-6. PubMed ID: 19853698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery.
    Börgermann J; Kanashnik A; Sossdorf M; Gummert J; Lösche W
    Platelets; 2010; 21(8):610-5. PubMed ID: 20807171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain.
    Lahoz-Rallo B; Blanco-Gonzalez M; Casas-Ciria I; Marín-Andrade JA; Mendez-Segovia JC; Moratalla-Rodriguez G; Quintero-Dominguez R; Ramirez-Raya M; Guerrero-Pinedo MJ; Aguilar-Diosdado M
    Diabetes Res Clin Pract; 2007 Jun; 76(3):436-44. PubMed ID: 17064808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of the antiaggregants ticlid and diabeton in correcting chronic intravascular microcoagulation of the blood in diabetic patients].
    Velikov VK; Saltykov BB; Galkina AK; Kabaeva EV; Frolova AI; Privalova EV; Savina TS; Zelenchuk NM; Shubina OI; Iarovaia LD
    Ter Arkh; 1991; 63(10):44-9. PubMed ID: 1805420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.
    Tan KT; Tayebjee MH; Lim HS; Lip GY
    Diabet Med; 2005 Dec; 22(12):1657-62. PubMed ID: 16401308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus.
    Kato H; Takashima T; Kishikawa H; Emura S; Ohmori K
    Int J Clin Pharmacol Res; 1996; 16(4-5):99-102. PubMed ID: 9172007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
    Randriamboavonjy V; Pistrosch F; Bölck B; Schwinger RH; Dixit M; Badenhoop K; Cohen RA; Busse R; Fleming I
    Circulation; 2008 Jan; 117(1):52-60. PubMed ID: 18071073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of aspirin resistance in patients with type 2 diabetes.
    Fateh-Moghadam S; Plöckinger U; Cabeza N; Htun P; Reuter T; Ersel S; Gawaz M; Dietz R; Bocksch W
    Acta Diabetol; 2005 Jun; 42(2):99-103. PubMed ID: 15944844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.